The mutations of a complex systemic disease like cancer can be modeled as stuck-at faults in the Boolean system paradigm. For a class of multiple faults, the fault identification is exceptionally significant under the incomplete access of all the underlying proteins of the system. A comprehensive linear framework has been developed in this manuscript to identify the class of faults under a set of homeostatic input conditions. An algorithm is developed to design new reporters to improve the observability. The other aspect of this manuscript lies in controlling the manifestation of the mutations, which is the essential objective of systems medicine research. The primary goal is to synthesize a cocktail of drug molecules (combination therapy) from a set of existing targeted drugs. The controllability results are included in this paper to understand the problem formally. An improvement of controllability algorithm is discussed to design new target drugs if the available drugs fail to accommodate the underlying fault set. The results are presented for Boolean maps and Boolean control networks. Biological examples are given to highlight the relevant results.
Introduction
The emergence of 'systems biology' opens up new frontiers in medicine and biology. One of the major challenges in modern medical science has been to provide a cure for complex systemic diseases like cancer, Alzheimer's, and Parkinson's, to name a few. Cancer is taken as the model system for the work in this manuscript. The futility of traditional therapeutic procedures in developing one wonder-drug to cure cancer has forced physicians to look into targeted combination therapy [1] [2] [3] . For the effective efforts towards the design of optimal combination therapy, it is required to have a reliable modeling scheme of the cancerous system such that a 'healthy' response, 'proliferating' response, and 'post-therapy' response can be compared quantitatively. With such modeling scheme, a drug optimization problems can be defined which bring all these responses quantitatively closer to minimize effects of a disease.
Kauffman [4] stated the possibility of modeling gene interactions with the Boolean network. The quantized states (ON and OFF) of the gene were represented as 0 and 1 in the logical domain. Since then, the Boolean modeling style has become famous among researchers [5] [6] [7] because of its discrete nature. The discrete nature helps to keep the computational complexity tractable for biological problems. Therefore,
Preliminaries

Variables in logical domain
Let a logical domain be defined as L = {T rue = 1, F alse = 0}.
Let u be the input variable and y be the output variable. For the logical domain,{u, y} ∈ L. d is a logical variable for a drug such that d = 1 means the drug is applied and d = 0 means the drug is not applied, i.e., d ∈ L. f is a ternary variable for a fault with values {sa-1, sa-0, no-fault} which are represented as f ∈ {−1, 0, 1}. For α number of primary inputs, the input state (Boolean vector) is defined as U = (u 1 , . . . , u α ), U ∈ {0, 1} α . Similarly, for β number of primary outputs, the output state is Y ∈ {0, 1} β ; for λ number of drugs, the drugs state is D ∈ {0, 1} λ ; and for γ number of faults, the fault state is F ∈ {−1, 0, 1} γ . The notations α, β, γ, and λ are used in this same context throughout the manuscript.
Boolean control network and Boolean map
Boolean control network
A Boolean control network (BCN) [4, [25] [26] [27] ] is a discrete-time, discrete-state, deterministic system. Due to the presence of a feedback loop, it can be perceived similar to a sequential network in Boolean domain.
Definition 2.1. : A BCN is a uniformly sampled discrete state dynamical system represented as:
where Ψ * : {0, 1} α × {0, 1} N → {0, 1} N and Γ * : {0, 1} α × {0, 1} N → {0, 1} β are two Boolean operators governing the dynamics of the BCN. N is the number of feedback variables, τ ∈ Z + is a non-negative discrete time index, and the feedback state X(τ ) ∈ {0, 1} N . The input state U (τ ) ∈ {0, 1} α , and the output state Y (τ ) ∈ {0, 1} β are the Boolean vectors as defined in Section 2.1.
Boolean map
A Boolean map (BM) is obtained by removing the feedback path from BCN, i.e., it behaves like a combinational network in Boolean domain.
Definition 2.2. : A BM is a non-feedback form of a BCN which relaxes a requirement for discrete uniform sampling, represented as:
where Γ * : {0, 1} α → {0, 1} β is the Boolean operator. t ∈ R + is a non-negative continuous time index.
Functions (Ψ * , Γ * ) for BCN and a function Γ * for BM are derived from biological information [11] .
Therefore, they are assumed to be known for the work in this paper.
Problem formulation in Boolean systems
A faulty BCN can be modeled by considering the faults as separate inputs to the system provided a fault-free BCN and the probable gene mutations (fault points). The drugs are also treated as external input variables in the known BCN topology. Without loss of generality, it is assumed that a fault-free BCN shown in (1) can be converted to define a faulty BCN as:
where Ψ :
is a faulty version of a fault-free BCN (Ψ * , Γ * ). The faults (F ) and drugs (D) are assumed to be constant over time, hence, the time stamp is not mentioned. Similarly, a fault-free BM shown in (2) can be converted to define the faulty BM as:
where Γ :
β . Γ is a modified BM after introduction of faults. Since the time indices of the input and output vectors of the BM are continuous in nature and devoid of causality, the indices can be omitted for all purposes. Hence (4) and all the subsequent analysis of BM no longer have a time stamp. The drugs (D) are inhibitory and are inherently different from the inputs (U ). The input U is mostly not under the control of the therapist for in situ modeling of a gene regulatory system. The inputs can be growth factors, hormones, oxygen, or different kind of molecular stresses [8] , whereas, drugs are user designed molecules targeted at known locations in Boolean systems. Hence the problem of control design in biological systems is finding drugs D. In both cases shown in (3) and (4), Ψ and Γ are assumed to be known because Ψ * and Γ * are known from their construction.
Semi-tensor products
For the conversion of logical expression into the linear form, the variables in the logical domain are required to map in the vector form. Let a vector (delta) set ∆ k be defined as ∆ k = {δ i k | i = 1, 2, . . . , k}, where δ i k is the i-th column of an identity matrix I k . A set ∆ 2 is used to denote the binary values, such that {1, 0} ∼ {δ 1 2 , δ 2 2 } respectively. Therefore, the variables defined in the logical domain are defined in the vector form given as, {u, y, d} ∈ ∆ 2 . Similarly, a vector set ∆ 3 is required to show a ternary variable in the vector form. Therefore, a vector form of fault variable is defined as f ∈ ∆ 3 , where δ 1 3 shows a sa-1 fault, δ 2 3 shows a sa-0 fault, and δ 3 3 shows a no-fault condition. Although f is not a binary variable, such multi-valued mapping has been done earlier in the literature [17] .
The logical operators Ψ and Γ are converted into linear operators using the semi-tensor product (STP) approach formulated in [28] [29] [30] [31] [32] . Definition 2.3. : Let M be the set of all matrices. Consider a matrix A ∈ M m×n and a matrix M ∈ B p×q . Let c be the least common multiple of n and p. Then the STP of A and B is defined as
where ⊗ is the Kronecker product of matrices. Remark 2.1. : Every matrix product has been assumed to be an STP throughout the paper. Therefore, the notation " " is mostly excluded.
For an STP of p k-valued logical variables, a mapping
Similarly, the output vector Y ∈ ∆ 2 β , the fault vector F ∈ ∆ 3 γ , and the drug vector D ∈ ∆ 2 λ .
Structure matrix
A structure matrix is derived from the network structure, and thus represents the characteristics of the network.
The dimensions of a structure matrix depend upon the dimensions of individual x i . In the matrix form,
Methodology
Structure matrix for faults and drugs
As mentioned in Section 2.3, a fault is modeled as an external input. Therefore, each fault changes the structure matrix of the network. If a node x is observed (by gene sequencing) to be mutated, its value is modified to x * . If the observed mutation is mapped as fault f , then the change in the value of x is given by the relation in matrix form as
is the structure matrix showing the effect of fault for different values of node x. For instance, if the original value of a node x is 0 (x = δ 2 2 ) and the fault observed is sa-1 (f = δ i.e., the value of x changes to 1 as an effect of fault.
Similarly, the application of an inhibitory drug d blocks the node x by changing its value to 0. When the drug is not applied, the node x retains its value. In logical form, it is represented as x * = x ·d [11] . Using the STP techniques [31] , this expression can be written in vector form as
. M D shows a structure matrix incorporating the effect of a drug applied at node x. The derivation of structure matrices M f and M d are provided in Section A of the Appendix. The matrices M f and M D are constant. For every fault f at a node x, x has to be replaced by M f xf to obtain a linear form. Similarly, for every inhibitory drug d at a node x, x has to be replaced by M D xd.
A linear form representation of BM and BCN
Let B be a set of matrices with all binary elements.
Boolean map
A linear form equation for BM is obtained by applying STP properties [31] on (4) to get a linear form representation as:
where Γ ∈ B 2 β ×2 α+λ 3 γ is a structure matrix of the BM.
Boolean control networks
Similar to BM, STP properties [31] are applied on (3) to get a linear form equation as:
where Ψ ∈ B 2 N ×2 α+λ+N 3 γ and Γ ∈ B 2 β ×2 α+N are the structure matrices of the BCN.
It is important to modify the system representation for extension applications like improvement in observability and controllability in such a way that the extensions become computationally tractable. Since the possible locations of the mutations are known in the BCN, a BCN model is divided into blocks. Block diagram for a BCN is given in Fig. 1 . Such block-wise division is possible with all the BCN and BM. The block diagram for the BCN consists of two main parts: primary block (indicated by L matrices) and the secondary block (indicated by H matrices). The primary block is further divided into sub-blocks, which are arranged level-wise based on the following rules:
Level 1 contains n 1 number of sub-blocks (with structure matrices L 1 i , i = 1, . . . , n 1 ) such that each sub-block depends on the input (including the state feedback), and only one fault or one drug. The secondary block is divided into the sub-blocks according to the following rules. Each sub-block (H 1 , . . . , H β ) depends upon the input and at least one output from level m (i.e. X 1 , . . . , X m ). Each sub-block has a single output, which is one of the primary outputs, and no sub-block has any fault or drug. The feedback input (X(τ − 1)) is taken from last level (L m ) of the sub-blocks and then it is applied to all sub-blocks of the primary block. The total number of sub-blocks in the network is given by:
This shows that the number of accessible nodes is limited. Since only one fault or one drug per subblock is allowed in the block-wise separation, the generation of modified structure matrix for any choice of faults and drugs becomes straightforward. It also becomes possible to directly access the important internal nodes (either the node is a mutation site or the node is a target for an available drug). A structure matrix is derived for a BCN using this block-wise design.
For the BM, the construction is identical except the state feedback link. The structure matrix calculations for BM are provided in Section B the Appendix. A similar process can be followed to obtain the structure matrices for BCN. The final form of the linear equation of BM can be represented as:
where H ∈ B 2 β ×2 α+λ 3 γ is a structure matrix of the BM. In comparison with (5), Γ = H for the BM structure. The final form of the linear equation of BCN can be expressed as:
where L ∈ B 2 N ×2 α+λ+N 3 γ and H ∈ B 2 β ×2 α+N are the structure matrices of BCN. (9) 
Results
The results for fault analysis and intervention for BM and BCN are derived from their structure matrices shown in (8) and (9) respectively. The inputs of the biological network are assumed to be experimentally readable. Therefore, the set of input vectors is assumed to be known experimentally. Before going to the theorems, let us introduce some variables. F 0 represents a fault vector, where all the γ faults are in 'nofault' state. Hence,
However in biology, the number of hazardous fault vectors is much less than 3 γ . Thus, the set of hazardous faults is defined as F ⊆ F. Let U represent the set of all (2 α ) input vectors. In the input space, only some inputs are homeostatic inputs, which are achievable in real biological systems. Thus, U ⊆ U represents the set of such permissible inputs. Let D be the set of all (2 λ ) drugs.
The next section discusses the main results of fault estimation and intervention along with some corollaries and proposition derived. If the available set of inputs fails to identify a particular fault uniquely, then it requires designing new output (reporters) to improve the observability. Similarly, if the drugs are not available for the estimated faults, the improvement in controllability is required. Algorithms 1 and 2 show such a possibility of improvement in observability and controllability of the network. The results are initially developed for the Boolean map and then extended for the Boolean control networks. 
Boolean map
The network information of BM is available in the structure matrix H represented by (8) . Therefore, the fault analysis and intervention results are derived from the structure matrix H. Theorem 4.1. : Existence theorem For a given input vector U ∈ U in a BM in (8) , the existence of fault vector F i is assured iff
Proof. : Necessary condition: For the specified input vector U ∈ U, a null-drug vector D 0 , and an arbitrary fault vector F i in a BM, output Y( U, F i , D 0 ) of the system is given by:
If a system with structure matrix H is fault-free or under the influence of null-fault vector F 0 , the output is given by: 
H is the modified structure matrix of the BM under null-drug vector D 0 . The above inequality trivially establishes that F i = F 0 . Hence it is sufficient to say that the inequality guaranties existence of fault vector F i . This completes the proof.
Corollary 4.1. : For a given fault vector F ∈ F in a BM in (8) , there exists an input vector U j ∈ U capable of detecting a fault vector F iff
Proposition 4.2. : For a specified input vector U ∈ U in BM in (8) , a set of fault vectors F U ⊆ F which is detectable by input vector U is given by
The following results discuss the necessary and sufficient conditions for detecting the existence of a particular fault using an arbitrary input. Proposition 4.3. : For a specified fault vector F ∈ F in a BM in (8), a set of input vectors U F ⊆ U which can detect the fault vector is given by:
where H = HW [ 
Proposition 4.5. : For a specified fault vector F ∈ F in a BM in (8), a set of input vectors U F ⊆ U which can uniquely identify a fault vector F is given by:
Proposition 4.6. : For a given set of input vectors U * ⊆ U, any input vector U i ∈ U * can detect a set of fault vectors F Ui (Proposition 4.2). The set of common fault vectors detectable by a set of given input vectors can be estimated as:
where ξ = card(U * ) is the cardinality of the set U * .
Proposition 4.7. : Let F be a set of permissible fault vectors for a BM in (8) and a fault vector F i ∈ F. Let U Fi be a set of input vectors that can detect a fault vector F i (see Proposition 4.3). Then, an input test set U T can be generated as:
where µ = card( F).
The test set generated by this method is not optimal, but it is useful to know the important homeostatic inputs and the fault coverage.
Proposition 4.8. : For a test set U T for a BM in (8), fault coverage F C ⊆ F is given by
where ζ = card(U T ) and F Ui is set of faults detectable by input vector U i ∈ U T (see Proposition 4.2).
Due to the limited number of homeostatic inputs, many of the fault vectors may remain undetectable in a real biological system. This affects the fault coverage. The following theorem provides a way to use multiple input vectors for unique fault detection. 
In Proposition 4.3, if some fault vector results in U F = ∅ then that fault vector is said to be undetectable. Such faults may not be harmful in the pathways under consideration, but may be harmful in other dependent pathways. Therefore it is important to detect such faults. In Corollary 4.2, if set F U * represents equivalent fault vectors, then fault detection becomes ambiguous or undetectable. For these conditions, a new reporter design is necessary. Some faults may not be detectable at primary outputs, but may be detectable at the output of internal blocks. Therefore, observability of faults at every internal node is used to decide a new reporter.
Let a set of undetectable fault vectors for a set of input vectors U be denoted as F U . Set F U contains all the faults for which U F = ∅ and the faults which are equivalent. Algorithm 1 results into best possible reporter(s) for improved fault detection. 3 Compute a set of detectable faults
It is possible in principle to put some additional constraints depending on some prior biological knowledge of certain nodes in choosing the best reporter in each iteration. The accessibility of the new reporters is restricted to the output nodes of the primary sub-blocks only. The number of such sub-blocks is γ + λ, which is small compared to the total number of internal nodes in the system keeping the computational complexity of the algorithm manageable. For the set of given input vectors U = δ 4 {1, 2, 3}, the fault coverage (Proposition 4.8) is F C = δ 9 {2, 4, 5, 6, 8}. However, for the set of input vectors U = δ 4 {2, 4}, fault coverage is F C = ∅. If a given set of fault vectors is F = δ 9 {1, 2, 3, 4, 8}, Corollary 4.2 says that using U = δ . Improvement in observability: It is evident from the matrix H that fault vectors in the set F U = δ 9 {1, 3, 7} are undetectable for control inputs U. It is required to improve the observability of the network to detect these faults. Therefore from Algorithm 1, a reporter can be designed as follows:
At node x Therefore the effects of the fault cannot be controlled with the available set of drugs.
Improvement in controllability:
For Proposition 4.12, if D F = ∅, then a new drug is required such that it can eliminate the effects of the faults. Let d λ+1 be a new drug. Then,
Naturally, the effect of faults will be maximum at the downstream protein(s) in the pathways. Although the secondary block does not have any fault or drug, a new drug can be targetted at the primary output of that block. These targets facilitate better possibilities of the drug intervention. Therefore, the best possible target site for the drug is searched from output towards input, level wise. Depending upon the target location of the drug, there are two possibilities. (i) Target point is internal node (x i j from primary block) of a BM, and (ii) target point is one of the primary outputs (secondary block) of a BM. For these two cases, similar to (8) , equation of the output can be written as
Details of the derivation process are provided in the Appendix (Section C). Algorithm 2 shows the process of improvement in controllability. However, all faults cannot be controlled with inhibitor type drugs. Some activator drugs are also required for improved control.
Algorithm 2: Improvement in controllability
Derive Y for chosen case ;
3
Find control set D F using Proposition 4.12 ;
Change target point ;
6
Repeat all steps ; 
Boolean control network
In (9), the information about network dynamics is shown by structure matrix L. As the secondary block is fault-free, a structure matrix L alone is sufficient for the fault analysis. The cyclic attractors in the state transitions of the BCN can be calculated from the diagonal of its structure matrix [31] . The number and sizes of the attractor cycles in the network change with the fault present. For each input vector and fault vector, a structure matrix L UF and its corresponding cycles are estimated. Assume that there are s different attractor cycles in the network. The cycles are numbered in the increasing size of their lengths. The length of an i th cycle is l i . For a cycle of length k, the corresponding diagonal elements of the structure matrix (L UF ) k become one [31] . Therefore, the diagonal values are used to identify changes in the attractor cycles for different conditions of the inputs and faults. Note that A B is the symmetric difference between the matrices A and B. T r(A) is the trace of a matrix A. Theorem 4.13. : Existence theorem For a given input U ∈ U in BCN L (9), the existence of a fault vector F i is ensured iff
where L UFi indicates resultant structure matrix L in the presence of input U and fault F i , l p is the length of a cycle in BCN L UF l p < l p+1 ; ∀p ∈ {1, . . . , s} , and l s is the length of a largest cycle among all L UF .
Proof. : Necessary condition: For the specified input U ∈ U, drug D 0 and the arbitrary fault F i in the BCN L, the state dynamics of the system is given by:
,
where N is the number of feedback nodes in the BCN. If the system L is fault-free, the state equation is
where all input conditions are kept identical. L UFi and L UF0 represent state transition matrices of the network. The diagonal of matrix (L UFi ) k represents states involved in cycles of length k and its proper factors.
difference between cycles cannot be estimated, and faults F i and F 0 become indistinguishable. If any value of
Therefore, the necessary condition
Sufficient condition: Suppose,
The above inequality states that attractor cycles produced in presence of fault F i and that of fault-free network are not same. Therefore it trivially establishes F i = F 0 . Hence it is sufficient to say that the inequality guaranties the existence of fault F i . This completes the proof.
Example 4.2. : Let number of feedback nodes (N ) inside the network be 3. Therefore, dimensions of matrix L UFi or L UF0 become 8 × 8. Assume that for some network, known input condition U and fault F i , the structure matrix is reduced to L UFi = δ 8 [3, 4, 6, 1, 1, 6, 8, 7] and L UF0 = δ 8 [5, 4, 6, 3, 1, 6, 2, 3] For
where L FUj indicates resultant structure matrix L in presence of input U j , fault F, l p is the length of a cycle in BCN L FU l p < l p+1 ; ∀p ∈ {1, . . . , s} , and l s is the size of a largest cycle among all L FU .
Assume that the cardinality of the permissible input set U is κ. A sequence π of inputs is a subset of U. Therefore, card(π) ≤ κ. The detection of the fault and design of intervention is more reliable when multiple input vectors are available. Hence, the fault analysis and intervention procedures are derived from the sequence of inputs.
Corollary 4.4. : For a given fault F ∈ F in BCN L (9), there exists a sequence π (card(π) ≤ κ) of inputs
where L Uj F indicates the resultant structure matrix L in presence of input U j and fault F. Note that the sequence of size card(π) is sufficient to detect the fault, and full sequence {U j , j = 1, . . . , κ} may not be required.
Theorem 4.14. : Uniqueness theorem For a specific fault F ∈ F in BCN L (9), input U ∈ U can uniquely identify fault F iff
Theorem 4.15. : Existence of control For BCN of (9) with fault vector F ∈ F and sequence π of control inputs, a drug vector
where L F indicates the resultant structure matrix L in presence of fault F.
Other result like the generalized uniqueness, improvement in observability, and improvement in controllability can be easily modified for BCN. Thus, those results for BCN are not shown in this manuscript.
Example 4.3. : Boolean equations for p53 pathways are given as [11] :
In these pathways, when p53 is 'active', it acts as a tumor suppressor (plausible fault location f 1 ) and Mdm2 is one of the target sites for application of drugs (d 1 ). Therefore, α = 1, λ = 1, γ = 1, and N = 4. Structure matrix L for the above equations is estimated as shown. L = δ 16 10, 10, 2, 2, 10, 10, 2, 2, 9, 9, 5, 5, 9, 9, 5, 5, |14, 10, 6, 2, 14, 10, 6, 2, 13, 9, 5, 5, 13, 9, 5, 5, |12, 12, 4, 4, 12, 12, 4, 4, 11, 11, 8, 8, 11, 11, 8, 8, |16, 12, 8, 4, 16,   12, 8, 4, 15, 11, 8, 8, 15, 11, 8, 8, |10, 10, 2, 2, 12, 12,   4, 4, 9, 9, 5, 5, 11, 11, 8, 8, |14, 10, 6, 2, 16, 12, 8, 4,   13, 9, 5, 5, 15, 11, 8, 8 , |10, 10, 2, 2, 10, 10, 2, 2, 9, 9, 13, 13, 9, 9, 13, 13, |14, 10, 6, 2, 14, 10, 6, 2, 13, 9, 13, p53 having 'stuck-at 0' results in proliferation. Therefore, it is important to detect this fault. Existence theorem: [16, 12, 8, 4, 16, 12, 8, 4, 15, 11, 8, 8, 15, 11, 8, 8] , [14, 10, 6, 2, 16, 12, 8, 4, 13, 9, 5, 5, 15, 11, 8, 8] , and k = {1, 7}.
This ensures the existence of fault F i = δ . Improvement in observability : Improvement is not required as 'stuck-at 0' fault is detectable. Existence of intervention: [12, 12, 4, 4, 12, 12, 4, 4, 11, 11, 16, 16, 11, 11, 16, 16] , [14, 10, 6, 2, 16, 12, 8, 4, 13, 9, 13, 13, 15, 11, 16, 16] , and k = {1}. [12, 12, 4, 4, 12, 12, 4, 4, 11, 11, 8, 8, 11, 11, 8, 8] , [14, 10, 6, 2, 16, 12, 8, 4, 13, 9, 5, 5, 15, 11, 8, 8] ,
is not useful. Improvement in controllability: Let the target for new drug d 2 be AT M , p53, or W ip1. Applying Algorithm 2, it is observed that target AT M shows some improvement in controllability. When DN A dsb = 0 and p53 is stuck-at 0, for target AT M , results obtained are as follows: [11, 11, 16, 16, 11, 11, 16, 16, 11, 11, 16, 16, 11, 11, 16, 16] , [12, 12, 4, 4, 12, 12, 4, 4, 11, 11, 16, 16, 11, 11, 16, 16] , [15, 11, 16, 16, 15, 11, 16, 16, 15, 11, 16, 16, 15, 11, 16, 16] , [14, 10, 6, 2, 16, 12, 8, 4, 13, 9, 13, 13, 15, 11, 16, 16] , and k = {1}.
Therefore drugs D 3 and D 1 are useful interventions. In logical equivalence, D 3 ∼ (1 1) and D 1 ∼ (0 1). Therefore, only drug d 2 is effective. This shows the effectiveness of the method in discarding certain drugs and selecting an appropriate therapeutic intervention. A suitable inhibitory drug at ATM may be useful for the stuck-at 0 fault at p53. This prediction shows that the method may prove to be helpful to decide the future research towards drugs discovery.
Conclusion
The manuscript describes a linear approach towards fault analysis and intervention in Boolean systems. The methodology opens up new problems towards fault analysis and intervention in Boolean systems. The proposed study considers the possibility of multiple faults (mutations) in feedback networks. The method does not require any test set considering the experimental difficulty in assigning test inputs to biological networks.
The objective of this work is to obtain the optimal therapeutic intervention with the available inputoutput information. In some cases, extra reporters may be required to analyze the mutations. If the none of drugs are useful from the available set, the improvement in controllability procedure suggests the new possible targets for the drugs. Although the method is exponential, the drug estimation time is still less than the treatment time of the patient. Also, the drugs obtained with the proposed work can be used to improve the lifespan of a patient and save the experimentation cost. Future work can be on the output based fault identification and control of BCN and the corresponding improvement in observability and controllability which have been described in this study. Fault analysis and control in the paradigms of asynchronous Boolean networks and probabilistic Boolean networks can also be taken into consideration in the near future. Substituting values using equation (15) ,
A Preliminaries
A.1 Generalization of matrices
where
Primary output vector Y of the BM depends on the secondary level. Inputs of secondary level are output vector from primary block and primary inputs of BM. Therefore equation of primary output vector is derived as:
Substituting X from equation (17),
where H *
Similarly, other primary outputs are defined as: 
